• 1
    Roach M3rd, Gandara DR, Yuo HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol. 1995; 13: 2606-2612.
  • 2
    Provatopoulou X, Athanasiou E, Gounaris A. Predictive markers of radiation pneumonitis. Anticancer Res 28( 4C): 2421-2432, 2008.
  • 3
    Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol. 2009; 27: 3370-3378.
  • 4
    Nikjoo H, O'Neill P, Wilson WE, Goodhead DT. Computational approach for determining the spectrum of DNA damage induced by ionizing radiation. Radiat Res. 2001; 156( 5 pt 2): 577-583.
  • 5
    Ward JF. The yield of DNA double-strand breaks produced intracellularly by ionizing radiation: a review. Int J Radiat Biol. 1990; 57: 1141-1150.
  • 6
    Yano K, Morotomi-Yano K, Adachi N, Akiyama H. Molecular mechanism of protein assembly on DNA double-strand breaks in the non-homologous end-joining pathway. J Radiat Res (Tokyo). 2009; 50: 97-108.
  • 7
    Ayene IS, Ford LP, Koch CJ. Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation. Mol Cancer Ther. 2005; 4: 529-536.
  • 8
    Bertolini LR, Bertolini M, Anderson GB, Maga EA, Madden KR, Murray JD. Transient depletion of Ku70 and Xrcc4 by RNAi as a means to manipulate the non-homologous end-joining pathway. J Biotechnol. 2007; 128: 246-257.
  • 9
    Chistiakov DA, Voronova NV, Chistiakov AP. Ligase IV syndrome. Eur J Med Genet. 2009; 52: 373-378.
  • 10
    Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and 3-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006; 66: 1399-1407.
  • 11
    Jin H, Tucker SL, Liu HH, et al. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiother Oncol. 2009; 91: 427-432.
  • 12
    Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events, version 3. Bethesda, MD: National Cancer Institute; 2003.
  • 13
    Tseng RC, Hsieh FJ, Shih CM, Hsu HS, Chen CY, Wang YC. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study. Cancer. 2009; 115: 2939-2948.
  • 14
    Hsu NY, Wang HC, Wang CH, et al. Lung cancer susceptibility and genetic polymorphism of DNA repair gene XRCC4 in Taiwan. Cancer Biomarkers. 2009; 5: 159-165.
  • 15
    Willems P, Claes K, Baeyens A, et al. Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. Genes Chromosomes Cancer. 2008; 47: 137-148.
  • 16
    Bau DT, Yang MD, Tsou YA, et al. Colorectal cancer and genetic polymorphism of DNA double-strand break repair gene XRCC4 in Taiwan. Anticancer Res. 2010; 30: 2727-2730.
  • 17
    Chiu CF, Tsai MH, Tseng HC, et al. A novel single nucleotide polymorphism in XRCC4 gene is associated with oral cancer susceptibility in Taiwanese patients. Oral Oncol. 2008; 44: 898-902.
  • 18
    Jeggo PA. DNA breakage and repair. Adv Genet. 1998; 38: 185-218.
  • 19
    Grawunder U, Zimmer D, Leiber MR. DNA ligase IV binds to XRCC4 via a motif located between rather than within its BRCT domains. Curr Biol. 1998; 8: 873-876.
  • 20
    Girard PM, Kysela B, Harer CJ, Doherty AJ, Jeggo PA. Analysis of DNA ligase IV mutations found in LIG4 syndrome patients: the impact of 2 linked polymorphisms. Hum Mol Genet. 2004; 13: 2369-2376.
  • 21
    O'Driscoll M, Cerosaletti KM, Girard PM, et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell. 2001; 8: 1175-1185.